The purpose of this Notice is to announce the participation
of National Institute of Allergy and Infectious Diseases (NIAID) in the PAR-11-044
"Indo-US Collaborative Program on Low-Cost Medical Devices (R03)" http://grants.nih.gov/grants/guide/pa-files/PAR-11-044.html,
provide some areas of interest to NIAID and to provide an NIAID contact.

NIAID is interested in research applications that address
chronic respiratory disease, primary immunodeficiencies, HIV and tuberculosis.

Under Background and Scope the following topics should be
added:

Diagnostic and Other Infectious Diseases devices suitable
for use in low resource settings.

Semi-quantitative HIV viral load

Tuberculosis diagnostics applicable to HIV
positive or negative patients with the following applications:

Distinguish latent, reactivation, or primary tuberculosis
infection.

Devices appropriate for use in BCG vaccinated populations.

Distinguish IRIS from recrudescence of tuberculosis during TB
treatment.

Improved detection of hepatic or renal toxicity due to TB
treatment.

Detection of TB in children, detection of paucibacillary TB,
detection of extrapulmonary TB.

Development of hand held ultrasound devices suitable for detection
of abscesses of lymph node enlargement.

hronic Respiratory Diseases monitoring and development.

Also under Background and Scope the bullet:

There is a need to screen newborns for treatable
conditions with high morbidity and mortality such as hemoglobinopathies,
hypothyroidism, and other metabolic or inherited disorders

Should now read:

There is a need to screen newborns for treatable conditions
with high morbidity and mortality such as hemoglobinopathies, primary
immunodeficiencies, hypothyroidism, and other metabolic or inherited disorders.

Components of
Participating Organizations
National Institute of Biomedical Imaging and Bioengineering
(NIBIB) (http://www.nibib.nih.gov)Eunice Kennedy Shriver National Institute of Child Health and Human Development
(NICHD)(http://www.nichd.nih.gov)

All other aspects of this Funding Opportunity Announcement remain
unchanged.